SARS-CoV-IN-5 

SARS-CoV-IN-5 (compound 49) is a highly selective, nonpeptidic and noncovalent 3CL^pro inhibitor with IC₅₀s of 38 nM, 21.1 nM and 86 nM for 3CL^pro of SARS-CoV-1, SARS-CoV-2, Bat coronavirus WIV1, respectively. SARS-CoV-IN-5 inhibits the replication of the SARS-CoV-2 delta variant with an EC₅₀ of 0.272 μM. SARS-CoV-IN-5 significantly reduces the lung viral copies in a K18-hACE2 transgenic mouse model. SARS-CoV-IN-5 has good target-specific and potential broad-spectrum anticoronavirus activities against SARS-CoV-1, WIV1, MERS, HCoV-OC43, HCoV-229E, and HKU9^[1].

SARS-CoV-2-IN-96 exhibits moderate inhibitory effects against the 3CL^pro of MERS-CoV (IC₅₀=1.68 μM), HCoV-OC43 (IC₅₀=0.94μM), HCoV-229E (IC₅₀=2.56 μM), and Bat coronavirus HKU9 (IC₅₀=0.402 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

629.48

C₂₈H₃₀BrFN₆O₅

O=C(N1CCN(C)CC1)C2=CC(Br)=CC([N+]([O-])=O)=C2N[C@H]3[C@H](CCCC3)NC(C(C4=CC=CC(F)=C4N5)=CC5=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhidong Jiang, et al. Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CL^pro Inhibitors as anti-SARS-CoV-2 Drug Candidate. J Med Chem. 2024 Aug 8;67(15):12760-12783.  [Content Brief]